Compare General Mills, Inc. (GIS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? General Mills, Inc. trades at $37.83 (market cap $19.89B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.2× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.55%). Which is the better fit depends on your goals.
| GIS | REGN | |
|---|---|---|
Market Cap | $19.89B | $83.19B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $812.27 |
52-Week Low | $32.17 | $555.51 |
Enterprise Value | $33.37B | $77.90B |
Dividend Yield | 6.55% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.89, up 2.27% today, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), though it beat Q2 2026 EPS estimates. Valuation appears attractive with P/E of 9.23 and P/S of 1.08. Recent news highlights cost-saving initiatives and new product launches, while analyst consensus remains cautious with 61% hold ratings.
Outlook: GIS faces headwinds from soft consumer demand and margin pressure, but its cost-saving strategy and dividend yield offer some stability. Risks include competitive threats and high debt levels. The stock presents a value opportunity for income-focused investors if management can execute its turnaround plan effectively.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
